Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2023 | Factors to consider when selecting between continuous and fixed-duration therapy in CLL

Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares some insights into factors to consider when selecting between fixed-duration and continuous therapy in patients with chronic lymphocytic leukemia (CLL). Dr Munir explains that treatment is guided by several factors, including genetics and comorbidities, and further highlights that patient choice is important when making this decision. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.